ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration … (ITNews)
December 11th, 2009
LEUVEN, Belgium, December 11 /PRNewswire/ — ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, announces today that it has started a Phase II trial of microplasmin for the treatment of exudative (wet) Age-related Macular Degeneration (AMD).
Original post by macular degeneration – Google News
(click on the author/publication link above to see full post)